Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • Log out
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Cancer Epidemiology, Biomarkers & Prevention
Cancer Epidemiology, Biomarkers & Prevention
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Null Results in Brief

No Association between Genetic Polymorphisms in IGF-I and IGFBP-3 and Prostate Cancer

Li Li, Mine S. Cicek, Graham Casey and John S. Witte
Li Li
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mine S. Cicek
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Graham Casey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John S. Witte
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published March 2004
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading
  • case-control study
  • insulin-like growth factors
  • (CA)n repeats
  • polymorphism
  • prostate cancer

Introduction

High levels of circulating insulin-like growth factor-I (IGF-I), or IGF-I in relation to IGF binding protein-3 (IGFBP-3), have been associated with an increased risk of prostate cancer (CaP) and other common epithelial cell malignancies (1). Twin studies estimate that 38% of the interindividual variability of IGF-I and up to 60% of that of IGFBP-3 are attributable to genetic factors (2). Recent work has identified a highly polymorphic cytosine-adenosine (CA)n dinucleotide repeat in the promoter region of the IGF-I gene and a single nucleotide polymorphism in the promoter region (−202) of the IGFBP-3 gene (3, 4). The IGF-I (CA)n repeat sequence is 1 kb upstream of the IGF-I transcription start site and contains specific regulatory elements (3, 4). Hence, we hypothesized that the length of (CA)n repeats might affect the transcription activity of the IGF-I gene, resulting in variable levels of IGF-I expression and affecting CaP risk or aggressiveness. Moreover, because previous studies have shown that the IGFBP-3 (−202) polymorphism is functional and is associated with circulating levels of IGFBP-3 (5), we anticipated that this variant might impact CaP risk as well.

Materials and Methods

The design of our study has been described in detail elsewhere (6). Briefly, we recruited a study population of 920 brothers (440 cases and 480 controls) from 414 discordant families (i.e., with at least one unaffected sibling) from the major medical institutions in the greater Cleveland, OH area and from the Henry Ford Health System in Detroit, MI. Institutional Review Board approval was obtained from the participating institutions and all study participants gave informed consent. Sibling sets consisted of probands with CaP diagnosed at age 73 or younger and at least one brother without CaP who was either older or no more than 8 years younger than the proband's age at diagnosis. This age restriction was selected in an attempt to increase the potential for genetic factors affecting disease, and to help make certain that the controls were not unaffected due simply to being of a younger age. The study population comprised of 91% Caucasian 8% African-American, and 1% Hispanic and Asian-American.

Genotyping was undertaken according to assays recently described elsewhere (3–5).

Statistical Analysis

We first calculated allele and genotype frequencies by disease status, and then estimated age-adjusted odds ratios (ORs) and 95% confidence intervals (CIs) by conditional logistic regression (matched on family) for the association between the polymorphisms and CaP. The IGF-I (CA)n repeat was modeled at the genotype- and allele-level. Because the most commonly reported CA repeat length is 19 (4, 5), we used the homozygous (CA19/CA19) as our referent for the genotype-level analysis, and created the following five genotype categories for comparison: (a) CA≤18/CA≤18; (b) CA≤18/CA19; (c) CA≤18/CA≥20; (d) CA19/CA≥20; and (e) CA≥20/CA≥20. We further collapsed these five comparison categories by combining those heterozygous for the 19 CA repeat (groups b and d above) and those without any 19 CA repeats (groups a, c, and e). At the allele level, we modeled chromosomes as a continuous variable, and with the following categorization: (a) CA19 (referent); (b) CA≤18; and (c) CA≥20. IGFBP-3 was modeled with its three genotype categories, CC (referent), AC, and AA. To investigate the potential effect of these polymorphisms on CaP aggressiveness, we undertook analyses stratified by the cases tumor stage and grade at diagnosis; men with tumor stage of ≥T2c or Gleason score ≥7 (and their control brothers) were categorized as having high stage/grade; others were considered low stage/grade. In our regression models, we investigated the potential confounding by age, height, and BMI; the latter two did not materially alter our results, and all results reported here are adjusted for age only.

Results and Discussion

One control's genotypes did not amplify, leaving 479 controls available for our analyses. No noteworthy differences were observed between the cases' and controls' frequency of IGF-I or IGFBP-3 polymorphisms, and neither of these was associated with CaP (Table 1). Specifically, for IGF-I (CA)n we observed no association regardless of how this was modeled (for brevity's sake, we only report results from allele-level analysis). And we found no association for the IGFBP-3 polymorphism, whether using a two-category model, or one that assumed a particular mode of inheritance (i.e., additive, dominant, or recessive). In particular, with an additive model, the trend-p from the logistic regression coefficient was >0.5 (others not shown). Stratifying these analyses by the cases' stage/grade of CaP, or age at diagnosis, did not materially alter our null results (not shown). Furthermore, restricting the analyses to Caucasians only did not affect our findings.

View this table:
  • View inline
  • View popup
Table 1.

Frequency of IGF-I and IGFBP-3 variants, and ORs and 95% CIs for their association with CaP in sibling-based study

By using a sibling-based design, our results are not susceptible to population stratification bias. But this design can be less efficient than a study of unrelated cases and controls. Nevertheless, our study had over 80% power to detect an OR ≥ 1.75 for the polymorphisms studied here. In conclusion, this moderately large case-control study did not detect an association between the IGF-I (CA)n repeats and IGFBP-3 (−202) polymorphisms and risk or aggressiveness of CaP. Because this is the first study to investigate this potential association, however, further research is warranted.

Footnotes

  • Grant support: NIH (CA88164, CA94211), Department of Defense (DAMD 17-98-1-8589), and Damon Runyon Cancer Research Foundation (CI-8 to L.L).

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Accepted October 24, 2003.
    • Received March 7, 2003.
    • Revision received June 5, 2003.

References

  1. ↵
    Yu H, Rohan T. Role of the insulin-like growth family in cancer development and progression. J Natl Cancer Inst, 2000;92:1472–89.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Harrela M, Koitinen H, Kaprio J, Lehtovirta M, Tuomilehto J, Eriksson J, et al. Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. J Clin Invest, 1996;98:2612–5.
    OpenUrlCrossRefPubMed
  3. ↵
    Weber JL, May PE. Abundant class of human polymorphisms which can be typed using the polymerase chain reaction. Am J Hum Genet, 1989;44:188–96.
    OpenUrl
  4. ↵
    Missmer SA, Haiman CA, Hunter DJ, Willett WC, Colditz GA, Speizer FE, et al. A sequence repeat in the insulin-like growth factor-1 gene and risk of breast cancer. Int J Cancer, 2002;100:332–6.
    OpenUrlCrossRefPubMed
  5. ↵
    Deal C, Ma J, Wilkin F, Paquette J, Rozen F, Ge B, et al. Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab, 2001;86:1274–80.
    OpenUrlCrossRefPubMed
  6. ↵
    Plummer SJ, Conti DV, Paris PL, Curran AP, Casey G, Witte JS. CYP3A4 and CYP3A5 genotypes, haplotypes and risk of prostate cancer. Cancer Epidemiol Biomarkers & Prev, 2003;12:928–32.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Cancer Epidemiology Biomarkers & Prevention: 13 (3)
March 2004
Volume 13, Issue 3
  • Table of Contents

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Epidemiology, Biomarkers & Prevention article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
No Association between Genetic Polymorphisms in IGF-I and IGFBP-3 and Prostate Cancer
(Your Name) has forwarded a page to you from Cancer Epidemiology, Biomarkers & Prevention
(Your Name) thought you would be interested in this article in Cancer Epidemiology, Biomarkers & Prevention.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
No Association between Genetic Polymorphisms in IGF-I and IGFBP-3 and Prostate Cancer
Li Li, Mine S. Cicek, Graham Casey and John S. Witte
Cancer Epidemiol Biomarkers Prev March 1 2004 (13) (3) 497-498;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
No Association between Genetic Polymorphisms in IGF-I and IGFBP-3 and Prostate Cancer
Li Li, Mine S. Cicek, Graham Casey and John S. Witte
Cancer Epidemiol Biomarkers Prev March 1 2004 (13) (3) 497-498;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Introduction
    • Materials and Methods
    • Results and Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Soft drink and juice consumption and renal cell carcinoma
  • Associations of ACEi and ARB with CRC Risk
  • Telomere length and TGCT risk
Show more Null Results in Brief
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Epidemiology, Biomarkers & Prevention

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Epidemiology, Biomarkers & Prevention
eISSN: 1538-7755
ISSN: 1055-9965

Advertisement